[Controlled application of cynarin in the treatment of hyperlipemic syndrome. Observations in 60 cases].
In a controlled trial 2 groups of 30 patients presenting various dislipidemic pictures were treated for 50 days with either 3,5-dihydroxy-1,4-bis-(3,4-dihydroxy-cinnamoyloxy)-cyclohexan-carbonic acid-(1) (cynarin, Listrocol) or placebo. Cynarin provied to be able to induce a significant reduction of the hypercholesteremia, the level of pre-beta-lipoproteins, the beta/alpha-lipoprotein ratio and patients' body weight. The administration of cynaria is, therefore, deemed useful in the prophylaxis and therapy of dislipidemic pictures of the arteriosclerotic disease.
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D001161:Arteriosclerosis / Q000517:prevention & control; D001835:Body Weight; D002784:Cholesterol / Q000097:blood; D002934:Cinnamates / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003920:Diabetes Mellitus / Q000517:prevention & control; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy*; D008075:Lipoproteins, HDL / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood; D008297:Male; D008875:Middle Aged; D013997:Time Factors; D014280:Triglycerides / Q000097:blood
D002934:Cinnamates; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D014280:Triglycerides; D002784:Cholesterol
Kontrollierte Anwendung von Cynarin in der Behandlung hyperlipämischer Syndrome. Beobachtungen von 60 Fällen